Epizyme and Eisai partner to use Epizyme's technology to discover, develop and commercialize histone methyltransferase inhibitors targeting enhancer of zeste homolog 2 (EZH2) for lymphoma and other cancers

Epizyme Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Eisai Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced